(Q53656515)

English

Detection of ALK rearrangements in malignant pleural effusion cell blocks from patients with advanced non-small cell lung cancer: a comparison of Ventana immunohistochemistry and fluorescence in situ hybridization.

scientific article published on 19 December 2014

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

16 May 2018

http://europepmc.org/abstract/MED/25529354

Detection of ALK rearrangements in malignant pleural effusion cell blocks from patients with advanced non-small cell lung cancer: a comparison of Ventana immunohistochemistry and fluorescence in situ hybridization. (English)

1 reference

Europe PubMed Central

PubMed publication ID

16 May 2018

http://europepmc.org/abstract/MED/25529354

immunohistochemistry

1 reference

based on heuristic

inferred from title

malignant pleural effusion

1 reference

based on heuristic

inferred from title

author name string

Weiya Wang

1

1 reference

Europe PubMed Central

PubMed publication ID

16 May 2018

http://europepmc.org/abstract/MED/25529354

Yuan Tang

2

1 reference

Europe PubMed Central

PubMed publication ID

16 May 2018

http://europepmc.org/abstract/MED/25529354

Jinnan Li

3

1 reference

Europe PubMed Central

PubMed publication ID

16 May 2018

http://europepmc.org/abstract/MED/25529354

Lili Jiang

4

1 reference

Europe PubMed Central

PubMed publication ID

16 May 2018

http://europepmc.org/abstract/MED/25529354

Yong Jiang

5

1 reference

Europe PubMed Central

PubMed publication ID

16 May 2018

http://europepmc.org/abstract/MED/25529354

Xueying Su

6

1 reference

Europe PubMed Central

PubMed publication ID

16 May 2018

http://europepmc.org/abstract/MED/25529354

publication date

19 December 2014

1 reference

Europe PubMed Central

PubMed publication ID

16 May 2018

http://europepmc.org/abstract/MED/25529354

Cancer Cytopathology

1 reference

Europe PubMed Central

PubMed publication ID

16 May 2018

http://europepmc.org/abstract/MED/25529354

123

1 reference

Europe PubMed Central

PubMed publication ID

16 May 2018

http://europepmc.org/abstract/MED/25529354

2

1 reference

Europe PubMed Central

PubMed publication ID

16 May 2018

http://europepmc.org/abstract/MED/25529354

117-122

1 reference

Europe PubMed Central

PubMed publication ID

16 May 2018

http://europepmc.org/abstract/MED/25529354

Global and regional estimates of cancer mortality and incidence by site: II. Results for the global burden of disease 2000

1 reference

https://api.crossref.org/works/10.1002%2FCNCY.21510

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCY.21510

21 January 2018

EGFR mutation status in tumour-derived DNA from pleural effusion fluid is a practical basis for predicting the response to gefitinib

1 reference

https://api.crossref.org/works/10.1002%2FCNCY.21510

21 January 2018

First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung

1 reference

https://api.crossref.org/works/10.1002%2FCNCY.21510

21 January 2018

Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR

1 reference

https://api.crossref.org/works/10.1002%2FCNCY.21510

21 January 2018

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCY.21510

21 January 2018

Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCY.21510

21 January 2018

Comparison of IHC, FISH and RT-PCR methods for detection of ALK rearrangements in 312 non-small cell lung cancer patients in Taiwan

1 reference

https://api.crossref.org/works/10.1002%2FCNCY.21510

21 January 2018

EML4-ALK testing in non-small cell carcinomas of the lung: a review with recommendations

1 reference

https://api.crossref.org/works/10.1002%2FCNCY.21510

21 January 2018

Testing for ALK rearrangement in lung adenocarcinoma: a multicenter comparison of immunohistochemistry and fluorescent in situ hybridization.

1 reference

https://api.crossref.org/works/10.1002%2FCNCY.21510

21 January 2018

ALK status testing in non-small cell lung carcinoma: correlation between ultrasensitive IHC and FISH.

1 reference

https://api.crossref.org/works/10.1002%2FCNCY.21510

21 January 2018

Diagnostic value of a novel fully automated immunochemistry assay for detection of ALK rearrangement in primary lung adenocarcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCY.21510

21 January 2018

An international interpretation study using the ALK IHC antibody D5F3 and a sensitive detection kit demonstrates high concordance between ALK IHC and ALK FISH and between evaluators

1 reference

https://api.crossref.org/works/10.1002%2FCNCY.21510

21 January 2018

Identification of non-small-cell lung cancer with activating EGFR mutations in malignant effusion and cerebrospinal fluid: rapid and sensitive detection of exon 19 deletion E746-A750 and exon 21 L858R mutation by immunocytochemistry.

1 reference

https://api.crossref.org/works/10.1002%2FCNCY.21510

21 January 2018

Identification of EGFR mutation, KRAS mutation, and ALK gene rearrangement in cytological specimens of primary and metastatic lung adenocarcinoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCY.21510

21 January 2018

p53 and FHIT mutations and microsatellite alterations in malignancy-associated pleural effusion

1 reference

https://api.crossref.org/works/10.1002%2FCNCY.21510

21 January 2018

The diagnostic accuracy of pleural effusion and plasma samples versus tumour tissue for detection of EGFR mutation in patients with advanced non-small cell lung cancer: comparison of methodologies

1 reference

https://api.crossref.org/works/10.1002%2FCNCY.21510

21 January 2018

Next-generation sequencing identifies and immunohistochemistry confirms a novel crizotinib-sensitive ALK rearrangement in a patient with metastatic non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCY.21510

21 January 2018

Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population

1 reference

https://api.crossref.org/works/10.1002%2FCNCY.21510

21 January 2018

A novel, highly sensitive antibody allows for the routine detection of ALK-rearranged lung adenocarcinomas by standard immunohistochemistry

1 reference

https://api.crossref.org/works/10.1002%2FCNCY.21510

21 January 2018

Screening of anaplastic lymphoma kinase rearrangement by immunohistochemistry in non-small cell lung cancer: correlation with fluorescence in situ hybridization.

1 reference

https://api.crossref.org/works/10.1002%2FCNCY.21510

21 January 2018

Immunohistochemical screening and fluorescence in situ hybridization confirmation of ALK translocation in lung adenocarcinoma and its clinicopathological significance: a single-center large-scale investigation of Chinese patients.

1 reference

https://api.crossref.org/works/10.1002%2FCNCY.21510

21 January 2018

Detection and comparison of epidermal growth factor receptor mutations in cells and fluid of malignant pleural effusion in non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCY.21510

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/CNCY.21510

1 reference

Europe PubMed Central

PubMed publication ID

16 May 2018

http://europepmc.org/abstract/MED/25529354

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

16 May 2018

http://europepmc.org/abstract/MED/25529354

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q53656515&oldid=2167009132"